Browsing Tag
BHV-7000
2 posts
Biohaven faces FDA partial clinical hold on new opakalim epilepsy enrollment
Biohaven has paused new enrollment across parts of its BHV-7000 epilepsy programme after an FDA partial clinical hold tied to incomplete metabolite data, while dosing continues in more than 600 randomized patients and one pivotal study remains fully enrolled.
Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology
Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026.